Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …

Abstract Background Nirmatrelvir/ritonavir (N/R) protects against severe outcomes after
SARS-CoV-2 (SCV2) infection, but patients and studies have described symptom and viral …

A clear understanding of real-world uptake of nirmatrelvir–ritonavir for treatment of SARS-
CoV-2 can inform treatment allocation strategies and improve interpretation of effectiveness …

Introduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We
identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …

Background Oral nirmatrelvir/ritonavir is a treatment for COVID-19, but whether treatment
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …

Background Nirmatrelvir with ritonavir (nirmatrelvir/r) is an oral antiviral COVID-19 treatment.
We report its efficacy to shorten time to sustained alleviation and resolution of COVID-19 …

Nirmatrelvir-ritonavir was developed for the treatment of COVID-19 and has shown efficacy
in a Phase 2/3 study of high risk patients (EPIC-HR1). Monitoring for the emergence of viral …

Background Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …